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Generation of a bile salt export 
pump deficiency model using 
patient-specific induced pluripotent 
stem cell-derived hepatocyte-like 
cells
Kazuo Imagawa1,2,3,*, Kazuo Takayama2,3,4,*, Shigemi Isoyama1, Ken Tanikawa5, 
Masato Shinkai6, Kazuo Harada7, Masashi Tachibana2, Fuminori Sakurai2,8, Emiko Noguchi9, 
Kazumasa Hirata7, Masayoshi Kage5, Kenji Kawabata10,11, Ryo Sumazaki1 & 
Hiroyuki Mizuguchi2,3,12
Bile salt export pump (BSEP) plays an important role in hepatic secretion of bile acids and its deficiency 
results in severe cholestasis and liver failure. Mutation of the ABCB11 gene encoding BSEP induces 
BSEP deficiency and progressive familial intrahepatic cholestasis type 2 (PFIC2). Because liver 
transplantation remains standard treatment for PFIC2, the development of a novel therapeutic option 
is desired. However, a well reproducible model, which is essential for the new drug development for 
PFIC2, has not been established. Therefore, we attempted to establish a PFIC2 model by using iPSC 
technology. Human iPSCs were generated from patients with BSEP-deficiency (BD-iPSC), and were 
differentiated into hepatocyte-like cells (HLCs). In the BD-iPSC derived HLCs (BD-HLCs), BSEP was 
not expressed on the cell surface and the biliary excretion capacity was significantly impaired. We 
also identified a novel mutation in the 5′-untranslated region of the ABCB11 gene that led to aberrant 
RNA splicing in BD-HLCs. Furthermore, to evaluate the drug efficacy, BD-HLCs were treated with 
4-phenylbutyrate (4PBA). The membrane BSEP expression level and the biliary excretion capacity in 
BD-HLCs were rescued by 4PBA treatment. In summary, we succeeded in establishing a PFIC2 model, 
which may be useful for its pathophysiological analysis and drug development.
Bile salt export pump (BSEP) is a key molecule for the generation of bile flow in humans1. BSEP deficiency 
causes severe intrahepatic cholestasis and liver failure. Progressive familial intrahepatic cholestasis (PFIC) is one 
of the cholestatic diseases in children, and PFIC type 2 (PFIC2) is a form of infantile cholestatic disorder that 
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occurs despite normal serum levels of gamma glutamyl transferase (GGT)2. PFIC2 is caused by mutations in 
the ABCB11 gene that encodes BSEP3. Certain mutations cause deficiency in the membrane expression of BSEP 
owing to accelerated proteasome-mediated degradation4–7. The main clinical features of BSEP-deficiency are 
severe jaundice, pruritus, and intrahepatic cholestasis, followed by liver failure and juvenile hepatobiliary car-
cinoma2,8,9. While orthotopic liver transplantation (OLT) is the major curative approach for BSEP-deficiency2,10, 
some BSEP-deficient patients treated with OLT experience a relapse of intrahepatic cholestasis due to the pres-
ence of autoimmune antibodies against BSEP11,12. Therefore, it is important to elucidate the pathophysiology of 
PFIC2 in order to develop novel therapies for its treatment.
Knockout mouse models are often used for the elucidation of disease mechanisms. However, 
Bsep/Abcb11-knockout mice are not a valid model for reproducing PFIC2 phenotypes because of species dif-
ferences in the functions of hepatic transporters13. Specifically, multiple drug resistance 1 (Mdr1) compensates 
for the biliary excretion functions of Bsep in mice, whereas no transporter compensates for these functions in 
humans14. To analyze the functions of mutated human ABCB11, BSEP-overexpressing cell lines are used widely. 
BSEP-overexpressing cells are useful for analyzing bile acid kinetics mediated by mutated BSEP, but not for ana-
lyzing the function of BSEP having mutations in the non-coding region of the ABCB11 or other genes. In fact, 
one-third of patients with PFIC harboring normal GGT do not have mutations in ABCB11 or ATP8B1 genes15,16. 
In addition, some ABCB11 mutations result in disruption of pre-mRNA splicing17. To perform pathological 
analysis of these mutations, primary human hepatocytes should be obtained from patients18. Therefore, a novel 
in vitro disease model containing the whole genome information of patients with BSEP-deficiency is necessary to 
further elucidate the disease mechanisms and BSEP regulation.
Human induced pluripotent stem cells (iPSCs) can be obtained by reprogramming somatic cells19. 
Patient-specific iPSCs and their derivatives are expected to offer novel disease models20. Moreover, the iPSC 
technology has already shown great potential for the discovery of new therapies against several diseases21. The 
utilization of patient-specific iPSCs and their derivatives would be advantageous for generating a disease model 
in humans, because the phenotype can be evaluated without consideration of species differences. In this study, 
human iPS cell-derived hepatocyte-like cells (HLCs) were generated from patients with BSEP-deficiency. As we 
have already established a highly efficient hepatocyte differentiation protocol, an almost homogenous hepatocyte 
population (more than 80%) could be generated from human iPS cells independently of iPS cell lines22,23. In this 
study, human iPSC lines were established from two patients with BSEP-deficiency (BD-iPSC), and then differ-
entiated into the HLCs. Finally, we examined whether the BD-iPSC derived HLCs (BD-HLCs) recapitulated the 
pathophysiology of PFIC2, specifically the aberrant splicing of ABCB11 mRNA, reduction of membrane BSEP 
expression and impairment of biliary excretion capacity.
Materials and Methods
Ethical statement. This study was approved by the ethics committees of the University of Tsukuba and 
the National Institutes of Biomedical Innovation, Health and Nutrition. All experiments were performed in 
accordance with relevant guidelines and regulations, and with the approval of the University of Tsukuba and the 
National Institutes of Biomedical Innovation, Health and Nutrition. Written informed consent was obtained from 
the participants or their parent.
Generation of human iPSCs from peripheral blood mononuclear cells. Peripheral blood mono-
nuclear cells (PBMCs) were separated from whole blood using Ficoll gradient separation, and then cultured 
with plate-bound anti-CD3 monoclonal antibody (Becton, Dickinson and Company) and X-VIVO10 medium 
(Lonza) containing 10 ng/mL recombinant IL-2 (Thermo fisher scientific). To generate human iPSCs from 
PBMCs, Yamanaka four factor-expressing Sendai-virus (SeV) vectors (CytoTune-iPS For Blood Cells; DNAVEC) 
was used24. Twenty-four hours after plating (1.87 × 105 cells/cm2), the PBMCs were transduced with the SeV 
vector at a multiplicity of infection (MOI) of 20. Twenty-four hours after the transduction, the medium was 
replaced with fresh X-VIVO 10 medium. The next day, the SeV-transduced PBMCs were plated onto a mitomycin 
C-treated EmbryoMax Primary Mouse Embryo Fibroblasts (MEF; Merck Millipore) feeder layer. The PBMCs 
were cultured with ReproStem (ReproCELL) medium containing 5 ng/mL fibroblast growth factor 2 (FGF2; 
Katayama Chemical Industries) for 2–3 weeks. The SeV genome cDNA synthesized from RNA of human iPSCs 
was amplified by RT-PCR using Ex Taq DNA polymerase (TaKaRa Bio Inc.). The PCR products were separated 
by electrophoresis on 2% agarose gels and visualized by staining with ethidium bromide. The SeV RNA genome 
was not detected in human iPSCs passaged more than 10 times (Figure S1D). The PCR primer sequences used in 
this study are described in Table S1.
Human ESCs/iPSCs Culture. Human embryonic stem cell (ESC) line, H9 (WiCell Research Institute), was 
maintained on MEF feeder layer with ReproStem medium supplemented with 5 ng/mL FGF2. Human ESCs were 
used following the Guidelines for Derivation and Utilization of Human Embryonic Stem Cells of the Ministry 
of Education, Culture, Sports, Science and Technology of Japan and furthermore, and the study was approved 
by Independent Ethics Committee. Human iPSC lines were maintained on MEF feeder layer with ReproStem 
medium supplemented with 10 ng/mL FGF2.
Primary Human Hepatocyte Culture. Platable cryopreserved human hepatocytes were purchased from 
VERITAS (lot YOW). The vials of hepatocytes were rapidly thawed in a shaking water bath at 37 °C, and then the 
contents of the vial were emptied into prewarmed Cryopreserved Hepatocyte Recovery Medium (CHRM, Life 
Technologies) and the suspension was centrifuged at 750 rpm for 10 min at room temperature. The hepatocytes 
were seeded at 1.25 × 105 cells/cm2 in HCM containing 10% FBS (Life Technologies) onto Cellmatrix Type I-A 
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acid-soluble type I collagen (Nitta Gelatin)-coated plates. The medium was replaced at 6 hr after seeding. The 
hepatocytes, which were cultured 48 hr after plating the cells, were used in the experiments.
Hepatocyte differentiation in vitro. For hepatocyte differentiation from human ESC and iPSC lines, the 
differentiated cells were constantly removed by manually picking them up. Before the initiation of hepatocyte 
differentiation, human ESCs/iPSCs were dissociated into clumps by using dispase (Roche Diagnostics) and plated 
onto BD Matrigel Basement Membrane Matrix Growth Factor Reduced (Becton, Dickinson and Company). 
These cells were cultured in the mouse embryo fibroblasts-conditioned medium for 3–4 days. The differentiation 
protocol for the induction of definitive endoderm cells, hepatoblast-like cells, and hepatocyte-like cells was based 
on our previous reports with some modifications22,23. Briefly, in the definitive endoderm differentiation, human 
ESCs/iPSCs were cultured with the L-Wnt3A-expressing cell (CRL2647; ATCC)-conditioned RPMI1640 medium 
(Sigma) containing 100 ng/mL Activin A (R&D Systems), 1% GlutaMAX (Thermo fisher scientific), 0.2% fetal 
bovine serum (FBS; Thermo fisher scientific), and 1 × B27 Supplement Minus Vitamin A (Thermo fisher scien-
tific) for 4 days. For the induction of hepatoblasts, the definitive endoderm cells were cultured with RPMI1640 
medium containing 30 ng/mL bone morphogenetic protein 4 (BMP4) (R&D Systems) and 20 ng/mL fibroblast 
growth factor 4 (R&D Systems), 1% GlutaMAX, and 1 × B27 Supplement Minus Vitamin A for 5 days. To perform 
the hepatocyte differentiation, the hepatoblasts were cultured with RPMI1640 medium containing 20 ng/mL 
hepatocyte growth factor (HGF) (R&D Systems), 1% GlutaMAX, and 1 × B27 Supplement Minus Vitamin A for 
5 days. Finally, the cells were cultured with hepatic maturation medium (hepatic maturation medium consists 
of Hepatocyte Culture Medium (HCM; Lonza, without epidermal growth factor (EGF)) containing 20 ng/mL 
oncostatin M (OsM) and 3% GlutaMAX) for 6 days. On day 20, the Matrigel solution (diluted by the hepatic 
maturation medium; the final Matrigel concentration was 0.25 mg/mL) was overlaid on the cells. The next day, 
the medium was changed with the hepatic maturation medium, and then the cells were cultured until day 25.
DNA sequence analysis. The exonic sequences of the ABCB11 gene were analyzed in the PBMCs/iPSCs 
of a control and patients with BSEP deficiency by direct sequencing of PCR products. The DNA was extracted 
from the PBMCs/iPSCs of a control and a patient with BD using a DNeasy Blood & Tissue Kit (Qiagen). The 
cDNA sequence of the ABCB11 gene was also analyzed by the direct sequencing of PCR products. The cDNA 
was synthesized from RNA of the Control, BD1 and BD2-HLCs. The PCR products were gel-purified, extracted 
with the GENECLEAN kit (MP Biomedical) according to the manufacturer’s instructions, and used as templates 
for the sequencing reaction with the Big Dye Terminator kit v3.1 (Applied Biosystems). Sequence analysis was 
performed by a Genetic Analyzer 3130 (Applied Biosystems). The sequences were compared to the reference 
sequence (GenBank accession number NM_003742.2). The nucleotide numbering was relative to the first adenine 
(+ 1) of initiation ATG codon. The PCR primer sequences used in this study are described in Table S2.
Biliary excretion index assay. To evaluate the biliary excretion capacity in vitro, the biliary excretion index 
(BEI) was calculated25,26. The Control, BD1, and BD2-HLCs on day 25 of culture were prepared, and then the 
cells were washed with HBSS buffer three times. Ten minutes after the cells were incubated with HBSS buffer or 
calcium-free HBSS buffer, the buffer was exchanged for HBSS buffer containing 5 μ m cholyl-lysyl- fluorescein 
(CLF), and the cells were incubated for 10 minutes. Uptake of CLF was stopped by adding cold HBSS buffer. The 
cells were washed with HBSS buffer, and lysed by 1% Triton X-100. The amount of CLF in the lysate was estimated 
by measuring the fluorescence at 492 nm and 536 nm by using a microplate reader (Genios, Tecan). BEI was cal-
culated as follows. BEI = 100*(HBSS-HBSS(Calcium free))/HBSS%
Results
Patients with BSEP-deficiency. A BSEP-deficient patient, named as BD1, was a 6-year-old girl. At the 
age of 3 months, she experienced severe jaundice and cholestasis with normal serum GGT levels. In addition, 
liver histological findings showed cholestasis, giant cell transformation, hepatocellular swelling (Fig. 1A, left), 
and negative BSEP immunostaining (Fig. 1B, left). At 8 months of age, due to liver failure, a successful OLT was 
performed. The clinical course since OLT has been good, and currently she does not have any hepatic or extrahe-
patic symptoms. She was diagnosed as having progressive cholestasis with normal-GGT and BSEP deficiency but 
there were no mutations in the exons of the ABCB11 gene. The other BSEP-deficient patient, named as BD2, was a 
13-year-old boy. He suffered from severe jaundice and cholestasis with normal serum GGT at the age of 2 months. 
Gene analysis of peripheral blood cells showed novel compound heterozygous mutations in the ABCB11 gene, 
c.− 24C > A (5′ -UTR; five prime untranslated region) and c.2417G > A (p.G806D). Trio analysis identified that 
these ABCB11 mutations were transmitted from the patient’s parents. Liver histological findings showed evidence 
for PFIC2; giant cell transformation, hepatocellular swelling, and cholestasis (Fig. 1A, middle). Consistently, liver 
immunohistochemistry indicated extremely low canalicular BSEP expression compared to control liver (Fig. 1B, 
middle). The other canalicular transporter, MRP2 was expressed in the BD2 patient’s liver to a degree similar to 
the control liver (Fig. 1C, middle). These findings were compatible with the typical symptoms of PFIC2. At 2 years 
of age, he underwent a successful liver transplantation from his mother. Clinical course since the procedure has 
been good, and the patient currently has no symptoms. Detailed information about these patients with BSEP-
deficiency is shown in Fig. 1D.
Generation of patient-specific iPSCs. An overview of human iPSC generation is shown in Figure S1A. 
Two patients with BSEP-deficiency (BD1 and BD2) were included in this study. To generate human iPSCs from 
these subjects, blood cells were collected, and the separated peripheral blood mononuclear cells (PBMCs) were 
transduced with Yamanaka four factor-expressing Sendai viral (SeV) vectors24. Twenty days after the SeV trans-
duction, BD1 and BD2-iPSC colonies were obtained. Control-iPSCs had been generated previously from the 
peripheral blood cells of a healthy female27.
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DNA sequence analyses showed that there were no differences in ABCB11 exons between the iPSCs and their 
parent PBMCs. This meant that the ABCB11 exonic mutations in BD2-iPSCs were consistently inherited from the 
parental PBMCs. Next, to characterize the human iPSC lines, immunostaining and real-time RT-PCR analyses of 
pluripotent markers were performed. Human iPSCs as well as ESCs (H9) were positive for OCT4, a pluripotency 
marker (Fig. S1B). The gene expression levels of the pluripotent markers (OCT4 and NANOG) in the iPSCs were 
higher than those in the PBMCs, and similar to those in human ESCs (Fig. S1C). We confirmed that the SeV 
RNA genome was not detected in human iPSCs (Fig. S1D). To examine whether the iPSCs have the ability to 
differentiate into cells of the three germ layers, embryoid bodies (EBs) were generated. Human iPSC-derived EBs 
were positive for the endodermal marker (AFP), mesodermal marker (cTnT), and ectodermal marker (Nestin) 
(Fig. S1E). The gene expression levels of the endodermal markers (AFP and TTR), mesodermal markers (NKX2.5 
and BRACHYURY), and ectodermal markers (NEUROD1 and PAX6) were higher in iPSC-derived EBs than in 
undifferentiated cells (Fig. S1F). Taken together, these results indicated that human iPSCs were successfully gen-
erated from patients with BSEP-deficiency.
Hepatocyte differentiation from human iPSCs. The protocol for hepatocyte differentiation was based 
on our previous report with some modifications (Fig. 2A)22,23. HLCs were overlaid with Matrigel on day 20 of 
hepatic cell differentiation, to promote the formation of bile canaliculi; the morphology was similar to that of 
human hepatocytes28. Moreover, transmission electron microscopy showed biliary canaliculi and tight junction 
structures in the HLCs (Fig. 2B). To investigate whether the biliary canaliculi were constructed between the 
HLCs, a bile secretion assay was performed using cholyl-lysyl-fluorescein (CLF), a fluorescent bile acid analog. 
CLF accumulation was detected in bile canaliculi of the Control-iPSC derived HLCs (Control-HLCs) over-
laid with Matrigel (Fig. S2). To estimate the hepatocyte differentiation capacity of the iPSCs, albumin (ALB) 
expression levels were examined by real-time RT-PCR, immunostaining, flow cytometry and enzyme-linked 
immuno-sorbent assay (ELISA). The ALB gene expression levels in the iPSC-HLCs were similar to those in pri-
mary human hepatocytes (PHH) plated for 48 h (Fig. 2C). The HLCs stained positively for ALB (Fig. 2D), and 
Figure 1. Pathological examination in liver sections. (A) Staining of liver sections with hematoxylin and 
eosin. Immunostaining analyses of liver sections with BSEP (B) and MRP2 (C) (original magnification: 400× ). 
(D) Characteristics of both the BSEP-deficient patients.
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Figure 2. Differentiation of human iPSCs into hepatocyte-like cells. (A) The protocol for hepatocyte 
differentiation from human ESCs (H9) and human iPSCs. (B) Left panel is a phase contrast image of 
Control-HLCs at day 25. Middle panel is a transmission electron microscopy image of Control-HLCs 
(original magnification: 9300×). Right panel shows a further magnified image. Black asterisk indicates the 
canalicular space. BC, bile canaliculus; TJ, tight junction; ER, endoplasmic reticulum; M, mitochondria; N, 
nucleus. (C) Gene expression levels of ALB in HLCs derived from H9 cells or human iPSCs as examined by 
real-time RT-PCR. The gene expression level in PHH was taken as 1.0. Data represent mean ± SD (n = 3). 
(D) Immunostaining analyses of ALB in the HLCs derived from H9 cells or human iPSCs. Nuclei were 
counterstained with DAPI. (E) Percentage of ALB-positive cells in HLCs derived from H9 cells or iPSCs, as 
measured by flow cytometry. Data represent mean ± SD (n = 3). (F) ALB secretion levels of HLCs derived from 
H9 cells or human iPSCs as examined by ELISA. Data represent mean ± SD (n = 8). Scale bars represent 20 μ m.
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the percentage of ALB-positive cells was more than 70% (Fig. 2E). In contrast, undifferentiated H9 cells were 
negative for ALB (Fig. 2D). The HLCs could abundantly secrete ALB into the culture medium (Fig. 2F). These 
results demonstrate that both efficient hepatocyte differentiation and comparative analysis of the HLCs could be 
achieved using our differentiation protocol.
Sequencing analysis of ABCB11 mRNA in the HLCs. Up to now, a mutation in the 5′ -UTR of the 
ABCB11 gene has not been reported in BSEP-deficiency2,10. To examine whether the ABCB11 mutation in the 
5′ -UTR mutation (c.-24C > A) would cause aberrant splicing in the HLCs derived from BD2-iPSCs (BD2-HLCs), 
direct sequence analysis of ABCB11 cDNA was performed. Exon 2 sequence of ABCB11 cDNA was heterozy-
gously eliminated in BD2-HLCs (Fig. 3A). This suggested aberrant splicing of ABCB11 in BD2-HLCs. A schematic 
Figure 3. Sequence analysis of ABCB11 mRNA using RNA extracted from the HLCs. (A) Sequence analysis 
of ABCB11 mRNA using RNA extracted from the Control, BD1, and BD2-HLCs. (B) A schematic diagram 
of wild type (WT) and mutant form (BD2 patient) of ABCB11 mRNA. (C) RT-PCR of normal and aberrantly 
spliced mRNA products of ABCB11 in the different HLCs.
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diagram of the predicted ABCB11 mRNA is presented in Fig. 3B (upper panel). In BD2-HLCs, aberrant splicing 
resulted in elimination of the proper initiation codon in ABCB11 (Fig. 3B, lower panel, the red mark indicates 
the 5′ -UTR mutation). These results suggested that the mutation in the 5′ -UTR of the ABCB11 gene (c.-24C > A) 
prevented normal BSEP translation. To investigate the aberrant splicing forms, RT-PCR analysis for ABCB11 
exons was performed, using primers (1F and 263R, Table S1) amplifying the region indicated in Fig. 3B. Agarose 
gel electrophoresis of the PCR product identified a smaller band of 160 bp in the BD2-HLC lane (Fig. 3C). The 
size of this PCR product was consistent with the size of aberrantly spliced form of ABCB11 containing exons 1, 3, 
and 4. A heterozygous missense ABCB11 gene mutation (c.2417G > A, p.G806D) was also observed in the tran-
scripts of BD2-HLCs (Fig. 3A). The pathogenicity of this novel missense mutation was predicted by Polyphen-2 
(Polymorphism Phenotyping V2, http://genetics.bwh.harvard.edu/pph2/) and SIFT (Sorting Intolerance From 
Tolerant, http://sift.jcvi.org/) tools, and its effect is anticipated to be damaging (Table S3).
Recapitulation of the PFIC2 phenotype using BD-HLCs. Next, we investigated whether the BD-HLCs 
could recapitulate the PFIC2 phenotype. The BSEP expression levels in the BD-HLCs were similar to those of 
Control-HLCs (Fig. 4A). In addition, farnesoid X receptor (FXR), which regulates the transcription of BSEP, 
was expressed in BD-HLCs (Fig. S3A). These results suggested that the expression level of BSEP transcripts in 
BD-HLCs was similar to that in Control-HLCs. To analyze the localization of BSEP in the HLCs, immunofluores-
cent double staining of BSEP and ZO-1 was performed, because ZO-1 is located on the canalicular membrane29. 
BSEP and ZO-1 were not co-localized in BD-HLCs, but were co-localized in the Control-HLCs (Fig. 4B, white 
arrow). This finding suggested that membrane BSEP was not expressed on BD-HLCs, which was also observed 
in the liver of the patients with BSEP deficiency (Fig. 1B, left and middle). It is also suggested that there might be 
a problem in BSEP trafficking in these two patients. Taken together, this data showed that BD-HLCs reproduced 
a pathological feature of PFIC2.
To investigate the capacity for bile acid uptake and synthesis in the BD-HLCs, the gene expression levels of 
the bile acid uptake transporter (Na+-taurocholate cotransporting polypeptide, NTCP) and bile acid synthesis 
enzyme (cytochrome P4507A1, CYP7A1) were examined by real-time RT-PCR. The gene expression levels of 
NTCP and CYP7A1 were higher in the BD-HLCs than in PHHs (Fig. S3B,C). These results indicated that the 
Figure 4. Analysis of BSEP expression and biliary excretion in the BD-HLCs. (A) Gene expression levels 
of BSEP in the HLCs as examined by real-time RT-PCR. The gene expression levels in PHH were taken as 1.0. 
Data represent mean ± SD (n = 3). (B) Immunofluorescence double staining of BSEP and ZO-1 in the different 
HLCs. White arrow indicates the co-localization of BSEP and ZO-1. (C) BEI of CLF-treated HLCs. Data 
represent mean ± SE (three independent differentiation experiments). Statistical significance was evaluated by 
one-way ANOVA in Tukey’s test. *P < 0.05. The scale bar represents 20 μ m.
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BD-HLCs had the capacity to take up and synthesize bile acid. Next, to evaluate the biliary excretion capacity of 
HLCs, the biliary excretion index (BEI) was calculated using CLF25,26. The BEI values of the BD-HLCs were signif-
icantly lower than those of the Control-HLCs (Fig. 4C). Taken together, these results showed that the BD-HLCs 
could reproduce the pathophysiology of PFIC2, specifically the impairment of biliary excretion.
Drug efficacy evaluation of 4PBA in the BD-HLCs. Finally, to investigate whether BD-HLCs could 
demonstrate measurable responses to therapeutic agents, we examined the drug efficacy of 4PBA, a promising 
drug for treating patients with PFIC230–33. It is known that 4PBA can improve membrane BSEP expression and 
biliary excretion capacity30. To investigate whether 4PBA treatment affected the BD-HLCs, the gene expression 
level of ALB was examined by real-time RT-PCR (Fig. 5A). No significant alteration of ALB gene expression levels 
was observed by 4PBA treatment, suggesting that 4PBA did not affect the hepatic function of the HLCs. Next, 
the BSEP gene expression level and membrane BSEP expression level in the 4PBA-treated HLCs were examined 
by real-time RT-PCR (Fig. 5B) and immunostaining (Fig. 5C), respectively. Although there was no significant 
alteration of BSEP expression level by this treatment, the membrane BSEP expression was increased by 4PBA 
treatment. These results suggested that 4PBA treatment did not promote transcriptional activation of BSEP, but 
altered other pathways, such as the pathway for membrane-protein trafficking and degradation4,34. In addition, 
the BEI was calculated to examine whether the biliary excretion capacity of the BD-HLCs could be rescued by 
4PBA treatment. The BEI in BD1-HLCs treated with 4PBA was significantly higher than that in these cells treated 
with solvent only (Fig. 5D). On the other hand, 4PBA treatment did not increase the biliary excretion capacity 
of BD2-HLCs. This might be explained by assuming that the biliary excretion capacity of the mutated BSEP was 
very low that is in agreement with the previous bioinformatics analyses of the mutated BSEP function (Table S3), 
although the membrane BSEP expression levels were increased by 4PBA treatment. These results suggested that 
the drug efficacy could be evaluated by using BD-HLCs.
Figure 5. Analysis of the BD-HLCs treated with 4-phenylbutyrate. The BD1, BD2, and Control HLCs were 
treated with 1 mM 4PBA for 24 hours. (A,B) Gene expression levels of ALB and BSEP in the HLCs as examined 
by real-time RT-PCR. The gene expression levels in solvent-treated HLCs were taken as 1.0. Data represent 
mean ± SD (n = 3). (C) Immunofluorescence staining of BSEP in the HLCs. The scale bar represents 20 μ m. 
(D) BEI of 4PBA-treated HLCs. Data represent mean ± SE (three independent differentiation experiments). 
Statistical significance was evaluated by Student’s t-test (n = 3). *P < 0.05.
www.nature.com/scientificreports/
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Discussion
The aim of this study was to examine whether HLCs derived from patients with BSEP-deficiency could 
reproduce the disease characteristics of PFIC2. We show here that the pathophysiologic features of PFIC2, 
i.e., abnormality of BSEP expression and impairment of biliary excretion, were reproduced in BD-HLCs. 
To the best of our knowledge, this is the first case generating a cholestatic disease model, using iPSC 
technology20.
One-third of patients with PFIC are not diagnosed genetically16. Recently, mutations in tight junction protein 2 
(TJP2) and FXR were found in patients with BSEP-deficiency, who harbored normal serum GGT and had no 
mutations in the ABCB11 genes15,35. However, the gene or mutation responsible for PFIC has not been iden-
tified in the BD1 patient or other BSEP-deficient patients with normal serum GGT10. The combination of iPS 
technology and next-generation sequencing technology is expected to provide some clues15,35–37. Future studies 
may reveal the function of novel PFIC-related genes identified using next-generation sequencing analysis with 
patient-specific iPSC-derived HLCs.
In this study, we identified two novel compound heterozygous ABCB11 mutations in c.-24C > A (5′ -UTR) 
and c.2417G > A (p.G806D) and demonstrated that the 5′ -UTR mutation resulted in aberrant splicing of 
mRNA followed by elimination of the proper initiation codon (Fig. 3A,B). The aberrantly spliced mRNA from 
the allele with this 5′ -UTR mutation (c.-24C > A) does not appear to be translated into a functional BSEP 
protein. Some studies have shown that the ABCB11 mRNA is aberrantly spliced in PFIC238; however, the 
effects of mutations in the 5′ -UTR of the ABCB11 gene have not been reported previously. As the expression 
of the ABCB11 gene is observed only in hepatocytes, the spliced form of ABCB11 mRNA cannot be analyzed 
using other types of cells. It is difficult to obtain biopsy samples of the liver, although blood cells and dermal 
fibroblasts are often used to analyze genomic DNA or mRNA. Thus, we were able to analyze aberrant splicing 
of ABCB11 gene using the HLCs instead of liver biopsy samples. The amino acid mutation (p.G806D) may 
also cause severe dysfunction of the BSEP protein as predicted by the Polyphen-2 and SIFT tools (Table S3). 
Accordingly, our data showed that the biliary excretion capacity of the BD2-HLCs was lower compared to 
Control-HLCs (Fig. 4C).
4PBA treatment promoted the membrane expression of BSEP (Fig. 5C). However, 4PBA treatment did not 
improve the capacity of bile secretion in BD2-HLCs (Fig. 5D). This discrepancy may be explained by the existence 
of mutation which causes defect in the transport activity. Consistently, Naoi et al. suggested that 4PBA may be an 
effective compound for patients with PFIC2 who retain transport activity of BSEP31. Because it is reported that 
CLF is also transported into bile canaliculi by not only BSEP but also other transporters39, it might be important 
to perform further analysis for evaluating BSEP function using the HLCs.
Our findings suggest a potential for dissecting PFIC2 pathogenesis at the cellular and molecular level in 
patient-specific HLCs. Our research also provides hope for discovering novel therapeutic options for treating 
BSEP deficiency and cholestasis in the future. In conclusion, this is the first report establishing a PFIC2 model in 
human hepatocytes, using iPSC technology. We believe that this model will promote further innovations in BSEP 
research.
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